CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Venetoclax

维奈克拉 杂质对照品Venetoclax Impurities

36 个杂质条目36 impurity entries

本页汇总 维奈克拉 的 36 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 36 impurity reference standards of Venetoclax. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 维奈克拉(Venetoclax)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesQuality by Design Based Chromatography Technique Development and Validation for the Medicine Venetoclax (for Chronic Leukemia), in the Context of Impurities Including Degradation Products
    Biomedical chromatography : BMC · 2025 · Dandabattina R et al.  ·  PMID 40174928  ·  DOI
  2. 杂质研究Impurity studiesIdentification, Synthesis, and Characterization of Potential Oxidative Impurities of Venetoclax: Application of Meisenheimer Rearrangement
    ACS omega · 2023 · Vaddamanu G et al.  ·  PMID 37867659  ·  DOI
  3. 杂质研究Impurity studiesOn the Stability and Degradation Pathways of Venetoclax under Stress Conditions
    Pharmaceutics · 2020 · Žigart N et al.  ·  PMID 32645956  ·  DOI
  4. 分析方法Analytical MethodsValidation of a LC-MS/MS Assay for Rapid and Simultaneous Quantification of Cobicistat and Venetoclax in Human Plasma and Serum
    Biomedical chromatography : BMC · 2025 · Westra N et al.  ·  PMID 40721345  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisPhotoredox and PIFA-mediated synthesis of N-aryl azacoumestanes: Antileukemic activity and venetoclax synergism in acute myeloid leukemia
    Bioorganic chemistry · 2026 · Novas RCV et al.  ·  PMID 42880119  ·  DOI

维奈克拉 —— 原料药与杂质对照品Venetoclax — drug substance & impurities

共 37 个条目(含原料药本体)37 items incl. the drug substance
Venetoclax structure
原料药 APIAPI
维奈克拉Venetoclax
Venetoclax
CAS No.1257044-40-8
Chemical FormulaC45H50ClN7O7S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 1 structure
1
维奈克拉杂质1Venetoclax Impurity 1
Venetoclax Impurity 1
CAS No.2097938-69-5
Chemical FormulaC45H48ClN7O8S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 2 structure
2
维奈克拉杂质2Venetoclax Impurity 2
Venetoclax Impurity 2
CAS No.2247750-11-2
Chemical FormulaC45H52ClN7O5S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 3 (Venetoclax N-Oxide) structure
3
维奈克拉杂质3 (维奈克拉氮氧化物)Venetoclax Impurity 3 (Venetoclax N-Oxide)
Venetoclax Impurity 3 (Venetoclax N-Oxide)
CAS No.2469279-00-1
Chemical FormulaC45H50ClN7O8S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 4 structure
4
维奈克拉杂质4Venetoclax Impurity 4
Venetoclax Impurity 4
CAS No.2227206-05-3
Chemical FormulaC19H28N2
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 4 Dihydrochloride structure
4
维奈克拉杂质4 双盐酸盐Venetoclax Impurity 4 Dihydrochloride
Venetoclax Impurity 4 Dihydrochloride
CAS No.2227206-06-4
Chemical FormulaC19H28N2·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 5 Monomer structure
5
维奈克拉杂质5 单体Venetoclax Impurity 5 Monomer
Venetoclax Impurity 5 Monomer
CAS No.1235865-77-6
Chemical FormulaC33H35ClN4O3
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 5 structure
5
维奈克拉杂质5Venetoclax Impurity 5
Venetoclax Impurity 5
CAS No.2254393-29-6
Chemical FormulaC33H35ClN4O3·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 6 structure
6
维奈克拉杂质6Venetoclax Impurity 6
Venetoclax Impurity 6
CAS No.1228837-05-5
Chemical FormulaC15H17ClO
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 8 structure
8
维奈克拉杂质8Venetoclax Impurity 8
Venetoclax Impurity 8
CAS No.2270190-88-8
Chemical FormulaC78H83Cl2N11O9S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 9 structure
9
维奈克拉杂质9Venetoclax Impurity 9
Venetoclax Impurity 9
CAS No.1235865-76-5
Chemical FormulaC34H37ClN4O3
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 10 structure
10
维奈克拉杂质10Venetoclax Impurity 10
Venetoclax Impurity 10
CAS No.2573767-92-5
Chemical FormulaC47H52ClN7O8S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 11 structure
11
维奈克拉杂质11Venetoclax Impurity 11
Venetoclax Impurity 11
CAS No.2573767-89-0
Chemical FormulaC26H32N6O12S2
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 12 structure
12
维奈克拉杂质12Venetoclax Impurity 12
Venetoclax Impurity 12
CAS No.2573767-94-7
Chemical FormulaC71H73ClN12O14S2
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 13 structure
13
维奈克拉杂质13Venetoclax Impurity 13
Venetoclax Impurity 13
CAS No.2573767-96-9
Chemical FormulaC45H50ClN7O8S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 14 structure
14
维奈克拉杂质14Venetoclax Impurity 14
Venetoclax Impurity 14
CAS No.2412506-53-5
Chemical FormulaC90H100N14O14S2
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 15 structure
15
维奈克拉杂质15Venetoclax Impurity 15
Venetoclax Impurity 15
CAS No.2573767-93-6
Chemical FormulaC78H83Cl2N11O9S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 16 structure
16
维奈克拉杂质16Venetoclax Impurity 16
Venetoclax Impurity 16
CAS No.2573767-91-4
Chemical FormulaC45H51N7O7S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 19 structure
19
维奈克拉杂质19Venetoclax Impurity 19
Venetoclax Impurity 19
CAS No.1228779-96-1
Chemical FormulaC12H17N3O5S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 20 structure
20
维奈克拉杂质20Venetoclax Impurity 20
Venetoclax Impurity 20
CAS No.2142574-09-0
Chemical FormulaC14H9FN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 21 structure
21
维奈克拉杂质21Venetoclax Impurity 21
Venetoclax Impurity 21
CAS No.2514648-06-5
Chemical FormulaC22H16N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 24 structure
24
维奈克拉杂质24Venetoclax Impurity 24
Venetoclax Impurity 24
CAS No.3091160-40-3
Chemical FormulaC45H50ClN7O8S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 29 structure
29
维奈克拉杂质29Venetoclax Impurity 29
Venetoclax Impurity 29
CAS No.1261761-91-4
Chemical FormulaC6H5ClN2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 34 structure
34
维奈克拉杂质34Venetoclax Impurity 34
Venetoclax Impurity 34
CAS No.1228780-49-1
Chemical FormulaC16H19ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 37 structure
37
维奈克拉杂质37Venetoclax Impurity 37
Venetoclax Impurity 37
CAS No.2180923-65-1
Chemical FormulaC26H24BrN5O7S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 38 structure
38
维奈克拉杂质38Venetoclax Impurity 38
Venetoclax Impurity 38
CAS No.2573767-90-3
Chemical FormulaC26H24FN5O7S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 49 structure
49
维奈克拉杂质49Venetoclax Impurity 49
Venetoclax Impurity 49
CAS No.1228943-80-3
Chemical FormulaC9H13ClO
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 50 structure
50
维奈克拉杂质50Venetoclax Impurity 50
Venetoclax Impurity 50
CAS No.105854-65-7
Chemical FormulaC9H13ClO
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 52 structure
52
维奈克拉杂质52Venetoclax Impurity 52
Venetoclax Impurity 52
CAS No.2270190-84-4
Chemical FormulaC56H69ClN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 53 structure
53
维奈克拉杂质53Venetoclax Impurity 53
Venetoclax Impurity 53
CAS No.1228780-72-0
Chemical FormulaC19H27ClN2
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 53 Dihydrochloride structure
53
维奈克拉杂质53 双盐酸盐Venetoclax Impurity 53 Dihydrochloride
Venetoclax Impurity 53 Dihydrochloride
CAS No.1628047-87-9
Chemical FormulaC19H27ClN2·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 59 structure
59
维奈克拉杂质59Venetoclax Impurity 59
Venetoclax Impurity 59
CAS No.3010987-19-3
Chemical FormulaC15H17ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 63 structure
63
维奈克拉杂质63Venetoclax Impurity 63
Venetoclax Impurity 63
CAS No.1257044-57-7
Chemical FormulaC19H20N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 64 structure
64
维奈克拉杂质64Venetoclax Impurity 64
Venetoclax Impurity 64
CAS No.1235865-75-4
Chemical FormulaC15H11FN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 66 structure
66
维奈克拉杂质66Venetoclax Impurity 66
Venetoclax Impurity 66
CAS No.93745-74-5
Chemical FormulaC6H5ClN2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 67 structure
67
维奈克拉杂质67Venetoclax Impurity 67
Venetoclax Impurity 67
CAS No.89581-72-6
Chemical FormulaC6H5ClN2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Venetoclax Impurity 70 structure
70
维奈克拉杂质70Venetoclax Impurity 70
Venetoclax Impurity 70
CAS No.65080-57-1
Chemical FormulaC9H14O
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

维奈克拉 —— 研究文献与合成路线Venetoclax — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 维奈克拉 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Venetoclax. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
    Žigart N, Črnugelj M, Ilaš J, et al. · Pharmaceutics · 2020 · 被引 5cited 5
  2. Quality by Design Based Chromatography Technique Development and Validation for the Medicine Venetoclax (for Chronic Leukemia), in the Context of Impurities Including Degradation Products
    Dandabattina R, Merugu KS, Bandaru LGR, et al. · Biomedical chromatography : BMC · 2025
  3. A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia
    Chakraborty S, Morganti C, Zaldana K, et al. · Leukemia · 2026 · 被引 7cited 7
  4. Leveraging venetoclax-induced autophagy to enhance AUTAC-mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia
    Elshazly AM, Hosseini N, Vangala JR, et al. · British journal of haematology · 2026
  5. Identification, Synthesis, and Characterization of Potential Oxidative Impurities of Venetoclax: Application of Meisenheimer Rearrangement
    Vaddamanu G, Goswami A, Nandipati RSR, et al. · ACS omega · 2023 · 被引 1cited 1
  6. Venetoclax-induced degradation of VP8* lectin domain disrupts group A rotavirus replication
    Zhao D, Li P, Zhang M, et al. · International journal of biological macromolecules · 2025

合成路线文献Synthetic-route papers

  1. Design, synthesis, and biological evaluation of novel HDAC3 PROTACs for combined therapy with Venetoclax in acute myeloid leukemia
    Chen Y, Liu E, Ding X, et al. · Bioorganic chemistry · 2026
  2. Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks
    Molica S, Lucignano M, Villa MR, et al. · European journal of haematology · 2026
  3. Identification, Synthesis, and Characterization of Potential Oxidative Impurities of Venetoclax: Application of Meisenheimer Rearrangement
    Vaddamanu G, Goswami A, Nandipati RSR, et al. · ACS omega · 2023

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

维奈克拉 杂质谱研究要点Venetoclax — impurity profiling notes

下面这些是拿到 维奈克拉 的 37 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 37 impurity entries for Venetoclax, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances